Le Lézard
Classified in: Science and technology, Business
Subjects: AWD, SVY

17 Greenberg Traurig Attorneys Named 2023 LMG Life Sciences Guide 'Life Science Stars'


Seventeen attorneys from global law firm Greenberg Traurig, LLP are recognized in the LMG Life Sciences Guide 2023 edition.

NEW YORK, Sept. 26, 2023 /PRNewswire-PRWeb/ -- Seventeen attorneys from global law firm Greenberg Traurig, LLP are recognized in the LMG Life Sciences Guide 2023 edition.

The LMG Life Sciences Guide is a resource for in-house counsel that identifies leading lawyers and firms in multiple practice areas, according to the publication's website. LMG Life Sciences' selection process involved over 1,000 online surveys and interviews with nearly 600 attorneys in the United States, as well as a review of public information and feedback from clients within the industry.

The following Greenberg Traurig attorneys are named 2023 "Life Science Stars":

In addition, Greenberg Traurig was recommended in the following practice areas:

About Greenberg Traurig's Life Sciences & Medical Technology Group: Greenberg Traurig's Life Sciences & Medical Technology Group advises clients ranging from start-ups to large multinational public companies to leading research institutions. The group's attorneys work closely with clients, providing innovative legal counsel to help them achieve their objectives ? from discovery through commercialization and product marketing.

About Greenberg Traurig: Greenberg Traurig, LLP has more than 2650 attorneys in 47 locations in the United States, Europe and the Middle East, Latin America, and Asia. The firm is a 2022 BTI "Highly Recommended Law Firm" for superior client service and is consistently among the top firms on the Am Law Global 100 and NLJ 500. Greenberg Traurig is Mansfield Rule 5.0 Certified Plus by The Diversity Lab. The firm is recognized for powering its U.S. offices with 100% renewable energy as certified by the Center for Resource Solutions Green-e® Energy program and is a member of the U.S. EPA's Green Power Partnership Program. The firm is known for its philanthropic giving, innovation, diversity, and pro bono. Web: http://www.gtlaw.com.

Media Contact

Rachel Perna, Greenberg Traurig, LLP, 312-364-1642, [email protected], https://www.gtlaw.com/en

SOURCE Greenberg Traurig, LLP


These press releases may also interest you

at 12:35
Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882. The data was also presented today by...

at 12:30
Blueprint Medicines Corporation today announced data showcasing its commitment to advance the scientific understanding and treatment of systemic mastocytosis (SM) at the 65th American Society of Hematology (ASH)...

at 12:05
Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today presented details from the Rallybio Fetal and...

at 12:05
Genmab A/S and AbbVie today announced new data from the ongoing phase 1/2 EPCOREtm NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall...

at 11:35
bluebird bio, Inc. ("bluebird bio" or "bluebird") today announced new and updated efficacy, safety and health-related quality of life (HRQoL) data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies of lovotibeglogene autotemcel...

at 11:35
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab-kxwh) in previously untreated or minimally...



News published on and distributed by: